Month: June 2025

IRVINE, Calif., June 23, 2025 (GLOBE NEWSWIRE) — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, recently participated in several prominent investor conferences throughout May and June 2025. SBC Medical delivered webcast presentations and conducted one-on-one meetings with institutional investors. Presentation videos can be viewed at the links below:https://youtu.be/sM8VzxrQpac?feature=shared Below is a summary of the Company’s participation in recent investor conferences:Zacks SCR Life Sciences Virtual Investor ForumMain Speaker: Yuya Yoshida (CFO)Date: June 12, 2025Sidoti Small-Cap Virtual ConferenceMain Speaker: Yuya Yoshida (CFO)Date: June 11, 2025Noble Capital Markets’ Emerging Growth Virtual Equity ConferenceMain Speaker:...

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano Med Promising tumor accumulation and attractive biodistribution shown in vivo, selective binding to membrane-bound MSLN with positive tumor to kidney ratioZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”) and Orano Med, a clinical-stage radiopharmaceutical company and a pioneer in the development of targeted alpha-particle therapies (TAT) with 212Pb (lead-212), today...

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety concerns in adults and adolescents with haemophilia A, with or without inhibitors1. Switching to Mim8 led to a sustained increase in thrombin generation into the normal range, but without causing thrombin levels that might pose a thrombotic risk1. FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with strong user preference over their emicizumab injection system2. These results add to the overall safety profile of Mim8 based on the FRONTIER clinical trial programme3.Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch...

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without...

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and key comorbidities EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that it will present new preclinical data supporting apelin receptor (APJ) agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The data will be presented at the American Diabetes Association’s 85th Scientific Sessions, held June 20–23,...

TORONTO, June 21, 2025 (GLOBE NEWSWIRE) — Canadian North Resources Inc. (“CNRI” or “the Company,” TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero) is pleased to announce the voting results of its Annual and Special Meeting of Shareholders held on June 19, 2025, in Mississauga, Ontario. A total of 73,621,572 common shares were voted at the Meeting, representing approximately 64.4% of the Company’s issued and outstanding common shares (114,325,317). Election of Directors Shareholders approved the re-election of all five nominees to the Board of Directors. The directors elected to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed are:Nominee % For % WithheldLee Q. Shim 99.99%   0.00%  Kaihui Yang 99.99%   0.00%  Aier Wang 99.99%   0.00%  Henderson Tse 99.99%   0.00%  Michael...

SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting taking place June 21-24, 2025 in New Orleans, Louisiana.Lead author Abstract Title Presentation DetailsStephen Graves [212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2-positive tumors in the VMT-α-NET-T101 trial Abstract Number: 251949Session Type: Poster & OralPoster Session Date: June 21, 2025Oral session: MTA07 Oncology: Clinical Diagnosis & Therapy Meet the Author Session, part 2 Oral Session Date: June 23, 2025Oral Session Time: 12:30 PM...

[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatmentSEATTLE, June 21, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”)...

MONTREAL, June 20, 2025 (GLOBE NEWSWIRE) — Jane Silverstone Segal, Chair of the Board of Directors of DAVIDsTEA Inc. (“DAVIDsTEA”) (TSXV: DTEA), announces that on June 20, 2025, she received shares of Rainy Day Investments Ltd. (“RDI”) by way of bequest from her late husband Mr. Herschel Segal, as a result of which Jane Silverstone Segal has voting control of RDI. RDI owns 12,012,538 common shares of DAVIDsTEA, representing 44.51% of DAVIDsTEA’s issued and outstanding common shares, which shares are now controlled by Jane Silverstone Segal. Immediately prior to the transfer of shares described above, Jane Silverstone Segal held 127,087 common shares of DAVIDsTEA, representing 0.47% of its 26,985,738 issued and outstanding common shares. Immediately after the transfer of shares described above, Mrs. Segal holds or exercises control,...